 Margaret Macy
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 12 | 2025 | 159 | 2.980 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 1742 | 1.390 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 165 | 1.370 |
Why?
| | Neoplasms | 17 | 2025 | 2681 | 1.340 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 98 | 1.170 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 907 | 0.880 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2024 | 45 | 0.870 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2024 | 40 | 0.860 |
Why?
| | Neoplasm Recurrence, Local | 11 | 2025 | 1057 | 0.830 |
Why?
| | Central Nervous System Diseases | 1 | 2024 | 72 | 0.790 |
Why?
| | Glioma | 5 | 2025 | 407 | 0.770 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 109 | 0.770 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2022 | 815 | 0.750 |
Why?
| | Piperazines | 1 | 2024 | 345 | 0.730 |
Why?
| | Glycolipids | 1 | 2021 | 42 | 0.710 |
Why?
| | Pyridines | 1 | 2024 | 494 | 0.680 |
Why?
| | Radiation Injuries | 2 | 2019 | 147 | 0.630 |
Why?
| | Indazoles | 2 | 2022 | 67 | 0.610 |
Why?
| | Bevacizumab | 2 | 2019 | 139 | 0.610 |
Why?
| | Brain Stem Neoplasms | 2 | 2017 | 83 | 0.600 |
Why?
| | Child | 41 | 2025 | 21921 | 0.590 |
Why?
| | Benzamides | 2 | 2022 | 213 | 0.590 |
Why?
| | Astrocytoma | 2 | 2017 | 128 | 0.590 |
Why?
| | Radiotherapy | 1 | 2019 | 207 | 0.570 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2025 | 801 | 0.570 |
Why?
| | Brain Diseases | 1 | 2019 | 148 | 0.560 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 230 | 0.560 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2022 | 231 | 0.550 |
Why?
| | Antineoplastic Agents | 10 | 2025 | 2152 | 0.550 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 230 | 0.540 |
Why?
| | Child, Preschool | 25 | 2025 | 11158 | 0.520 |
Why?
| | 3-Iodobenzylguanidine | 3 | 2025 | 8 | 0.480 |
Why?
| | Adolescent | 30 | 2025 | 21564 | 0.450 |
Why?
| | Brain Neoplasms | 5 | 2022 | 1267 | 0.410 |
Why?
| | Sarcoma | 2 | 2015 | 189 | 0.410 |
Why?
| | Prognosis | 11 | 2025 | 3984 | 0.380 |
Why?
| | Rhabdomyosarcoma | 2 | 2025 | 74 | 0.360 |
Why?
| | Piperidines | 2 | 2025 | 216 | 0.350 |
Why?
| | Quinazolines | 2 | 2023 | 249 | 0.350 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 78 | 0.340 |
Why?
| | Biomarkers, Tumor | 4 | 2022 | 1224 | 0.340 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2010 | 26 | 0.340 |
Why?
| | Maximum Tolerated Dose | 6 | 2025 | 204 | 0.330 |
Why?
| | Humans | 49 | 2025 | 138651 | 0.310 |
Why?
| | Glioblastoma | 1 | 2012 | 341 | 0.290 |
Why?
| | Leukemia | 1 | 2010 | 239 | 0.280 |
Why?
| | DNA Damage | 1 | 2010 | 422 | 0.280 |
Why?
| | Young Adult | 14 | 2025 | 13305 | 0.270 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2025 | 633 | 0.250 |
Why?
| | Male | 28 | 2025 | 68260 | 0.240 |
Why?
| | Medical Oncology | 2 | 2024 | 304 | 0.240 |
Why?
| | Liver Neoplasms | 1 | 2012 | 712 | 0.240 |
Why?
| | Survival Rate | 6 | 2025 | 1935 | 0.230 |
Why?
| | Female | 28 | 2025 | 73763 | 0.230 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 285 | 0.230 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5112 | 0.230 |
Why?
| | Camptothecin | 2 | 2017 | 122 | 0.230 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1746 | 0.230 |
Why?
| | Cyclin D | 1 | 2024 | 9 | 0.220 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2024 | 415 | 0.220 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2025 | 131 | 0.210 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 73 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2025 | 2049 | 0.210 |
Why?
| | Neoplasm Staging | 3 | 2024 | 1372 | 0.210 |
Why?
| | Bone Neoplasms | 2 | 2024 | 246 | 0.210 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1111 | 0.210 |
Why?
| | Antibodies, Monoclonal | 4 | 2025 | 1436 | 0.210 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 227 | 0.200 |
Why?
| | Sirolimus | 2 | 2016 | 277 | 0.200 |
Why?
| | Infant | 11 | 2025 | 9574 | 0.190 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2024 | 203 | 0.190 |
Why?
| | Pediatrics | 2 | 2020 | 1078 | 0.190 |
Why?
| | Osteosarcoma | 1 | 2023 | 73 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 540 | 0.180 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 150 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2024 | 442 | 0.180 |
Why?
| | Central Nervous System | 1 | 2024 | 263 | 0.180 |
Why?
| | Gangliosides | 1 | 2021 | 21 | 0.180 |
Why?
| | Sulfonamides | 1 | 2025 | 505 | 0.170 |
Why?
| | Adult | 16 | 2025 | 38201 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 368 | 0.170 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 157 | 0.170 |
Why?
| | Salvage Therapy | 2 | 2019 | 151 | 0.170 |
Why?
| | Necrosis | 2 | 2019 | 248 | 0.160 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 64 | 0.160 |
Why?
| | Pyridazines | 1 | 2020 | 55 | 0.160 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2527 | 0.150 |
Why?
| | Etoposide | 3 | 2017 | 162 | 0.150 |
Why?
| | Dexamethasone | 2 | 2019 | 375 | 0.150 |
Why?
| | Imidazoles | 1 | 2020 | 239 | 0.150 |
Why?
| | Lymphoma | 1 | 2019 | 227 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1235 | 0.140 |
Why?
| | Taxoids | 1 | 2018 | 101 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 216 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 80 | 0.130 |
Why?
| | Heterocyclic Compounds | 1 | 2017 | 22 | 0.130 |
Why?
| | Incidence | 1 | 2024 | 2747 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2018 | 190 | 0.130 |
Why?
| | Cetuximab | 1 | 2017 | 98 | 0.130 |
Why?
| | Glucocorticoids | 2 | 2019 | 528 | 0.130 |
Why?
| | Azacitidine | 1 | 2017 | 139 | 0.120 |
Why?
| | Cytarabine | 3 | 2025 | 63 | 0.120 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1034 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 661 | 0.120 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 140 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2025 | 10923 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2019 | 980 | 0.110 |
Why?
| | Thyroxine | 1 | 2014 | 64 | 0.100 |
Why?
| | Pilot Projects | 1 | 2019 | 1765 | 0.100 |
Why?
| | Hypothyroidism | 1 | 2014 | 73 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2024 | 15909 | 0.100 |
Why?
| | Oxides | 1 | 2013 | 47 | 0.100 |
Why?
| | Arsenicals | 1 | 2013 | 30 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 756 | 0.100 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 48 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2022 | 431 | 0.100 |
Why?
| | Leucovorin | 1 | 2012 | 85 | 0.100 |
Why?
| | DNA Methylation | 1 | 2017 | 629 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 310 | 0.090 |
Why?
| | Animals | 4 | 2021 | 37217 | 0.090 |
Why?
| | Fluorouracil | 1 | 2012 | 204 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3637 | 0.090 |
Why?
| | Spinal Cord | 1 | 2014 | 373 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.090 |
Why?
| | HL-60 Cells | 1 | 2010 | 33 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 89 | 0.080 |
Why?
| | Consensus | 2 | 2025 | 685 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2010 | 92 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 761 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 984 | 0.080 |
Why?
| | Drug Synergism | 1 | 2010 | 368 | 0.080 |
Why?
| | Brain | 2 | 2014 | 2792 | 0.080 |
Why?
| | Pons | 1 | 2009 | 29 | 0.080 |
Why?
| | Methotrexate | 1 | 2010 | 255 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 549 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2022 | 6144 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 631 | 0.080 |
Why?
| | Recurrence | 2 | 2010 | 1084 | 0.070 |
Why?
| | Doxorubicin | 1 | 2010 | 348 | 0.070 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 103 | 0.070 |
Why?
| | Molecular Targeted Therapy | 2 | 2022 | 413 | 0.070 |
Why?
| | Drug Design | 1 | 2008 | 165 | 0.070 |
Why?
| | Acute Disease | 1 | 2010 | 994 | 0.070 |
Why?
| | Cell Cycle | 1 | 2010 | 592 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1123 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 322 | 0.060 |
Why?
| | Genomics | 2 | 2022 | 796 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3433 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5697 | 0.060 |
Why?
| | Topotecan | 1 | 2025 | 13 | 0.060 |
Why?
| | Everolimus | 1 | 2025 | 110 | 0.060 |
Why?
| | Phenylurea Compounds | 1 | 2025 | 95 | 0.050 |
Why?
| | Disease Progression | 1 | 2012 | 2749 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2024 | 24 | 0.050 |
Why?
| | RNA-Binding Protein EWS | 1 | 2024 | 25 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 255 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2025 | 205 | 0.050 |
Why?
| | Europe | 1 | 2025 | 407 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2815 | 0.050 |
Why?
| | Mice | 1 | 2021 | 17814 | 0.050 |
Why?
| | Quinolines | 1 | 2025 | 150 | 0.050 |
Why?
| | Vincristine | 1 | 2024 | 129 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2024 | 411 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2480 | 0.050 |
Why?
| | Lactams, Macrocyclic | 1 | 2023 | 50 | 0.050 |
Why?
| | Gene Amplification | 1 | 2023 | 102 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 48 | 0.050 |
Why?
| | Aminopyridines | 1 | 2023 | 102 | 0.050 |
Why?
| | Oncogenes | 1 | 2022 | 118 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2546 | 0.040 |
Why?
| | Pyrazoles | 1 | 2025 | 425 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2022 | 195 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1806 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 215 | 0.040 |
Why?
| | Drug and Narcotic Control | 1 | 2020 | 29 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 195 | 0.040 |
Why?
| | United States | 3 | 2025 | 14938 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 336 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 243 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2022 | 620 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 2174 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 349 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 73 | 0.040 |
Why?
| | Isotretinoin | 1 | 2018 | 24 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 116 | 0.040 |
Why?
| | Azepines | 1 | 2018 | 97 | 0.030 |
Why?
| | Hematologic Diseases | 1 | 2018 | 66 | 0.030 |
Why?
| | Daunorubicin | 1 | 2017 | 24 | 0.030 |
Why?
| | Precision Medicine | 1 | 2021 | 424 | 0.030 |
Why?
| | Benzylamines | 1 | 2017 | 43 | 0.030 |
Why?
| | Blepharoptosis | 1 | 1997 | 12 | 0.030 |
Why?
| | Genes, Dominant | 1 | 1997 | 97 | 0.030 |
Why?
| | Immunotherapy | 1 | 2022 | 634 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 704 | 0.030 |
Why?
| | Treatment Failure | 1 | 2018 | 351 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1997 | 71 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 87 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2018 | 215 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 95 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 206 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 896 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 122 | 0.030 |
Why?
| | Pyrimidines | 1 | 2018 | 472 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 220 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2339 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3256 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1233 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 639 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1317 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2727 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 305 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3987 | 0.020 |
Why?
| | Radiography | 1 | 2014 | 841 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 5086 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7554 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 309 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2698 | 0.020 |
Why?
| | Radiosurgery | 1 | 2009 | 389 | 0.010 |
Why?
| | Aged | 1 | 2024 | 24024 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 33604 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2954 | 0.010 |
Why?
| | Lod Score | 1 | 1997 | 64 | 0.010 |
Why?
| | Genetic Markers | 1 | 1997 | 342 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1997 | 502 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 1997 | 206 | 0.010 |
Why?
| | Pedigree | 1 | 1997 | 511 | 0.010 |
Why?
| | Genotype | 1 | 1997 | 1842 | 0.010 |
Why?
|
|
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|